Paper Details

  1. Home
  2. Paper Details

Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.

Author: , Aparicio-DomínguezMario, Arias-SantiagoSalvador, Belinchón-RomeroIsabel, Berenguer-RuizSonsoles, Carretero-HernándezGregorio, DaudénEsteban, Del AlcázarElena, Eiris-SalvadoNoemí, FerranMarta, Garcia-Latasa de AranibarFrancisco Javier, González-CanteroÁlvaro, Herranz-PintoPedro, Hospital-GilMercedes, Llamas-VelascoMar, López-FerrerAnna, Mateu-PuchadesAlmudena, Rivera-DiazRaquel, Rocamora-DuránVicenç, Rodríguez Fernández-FreireLourdes, Ruíz-GenaoDiana, Ruíz-VillaverdeRicardo, Salgado-BoqueteLaura, Santos-AlarcónSergio, Santos-JuanesJorge, de la CuevaPablo

Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Tildrakizumab is effective and safe in real-world practice for treating moderate-to-severe plaque psoriasis. This retrospective, observational study of 190 patients found that tildrakizumab achieved significant PASI reduction at 24 weeks, with high rates of PASI ≤3 and ≤1. The rate of adverse events was low, with infections being the most common.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Tildrakizumab is a humanized, IgG1/κ antibody that interacts with the p19 subunit of interleukin 23. It is approved for the treatment of moderate-to-severe plaque psoriasis. Real-world evidence on the effectiveness and safety of tildrakizumab is limited. OBJECTIVES: To assess the effect...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/jdv.19468

データ提供：米国国立医学図書館（NLM）

Tildrakizumab for Psoriasis: Real-World Effectiveness and Safety

This retrospective, observational, multicentre study assesses the effectiveness and safety of tildrakizumab, a humanized antibody targeting the p19 subunit of interleukin 23, for treating moderate-to-severe plaque psoriasis in routine clinical practice. The study analyzed data from 190 patients treated with tildrakizumab at 24 weeks. The study found that tildrakizumab was effective in reducing psoriasis severity, with a mean PASI reduction of 88.79% at week 24. At 6 months, 87.1% of patients achieved PASI ≤3, and 40.3% achieved PASI ≤1. The study also found that tildrakizumab was generally safe, with a low rate of adverse events. The most frequent adverse events were infections.

Tildrakizumab: A Promising Treatment for Psoriasis

The study provides real-world evidence supporting the effectiveness and safety of tildrakizumab for treating moderate-to-severe plaque psoriasis. The findings confirm the drug's efficacy in reducing psoriasis severity and highlight its favorable safety profile.

Navigating Psoriasis Treatment Options

Patients with psoriasis should discuss their treatment options with their healthcare providers to determine the best approach based on their individual needs and preferences. The study's findings provide valuable information for healthcare professionals considering tildrakizumab as a treatment option for psoriasis.

Dr.Camel's Conclusion

Just like a camel seeking relief from the harsh desert sun, patients with psoriasis are looking for effective treatments to alleviate their symptoms. This study provides encouraging real-world evidence for the effectiveness and safety of tildrakizumab, offering a promising avenue for managing this challenging skin condition. It's a reminder that even in the face of complex medical conditions, there are ongoing efforts to develop effective and safe treatments to improve the lives of patients.

Date :
  1. Date Completed 2023-12-05
  2. Date Revised 2023-12-05
Further Info :

Pubmed ID

37625815

DOI: Digital Object Identifier

10.1111/jdv.19468

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.